Kodiak Sciences (KOD) Competitors $6.65 +0.08 (+1.22%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.78 +0.13 (+1.95%) As of 08/1/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KOD vs. ARQT, IMCR, SPRY, TARS, ADPT, SDGR, JANX, ABCL, EVO, and EWTXShould you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Arcutis Biotherapeutics (ARQT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Tarsus Pharmaceuticals (TARS), Adaptive Biotechnologies (ADPT), Schrodinger (SDGR), Janux Therapeutics (JANX), AbCellera Biologics (ABCL), Evotec (EVO), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. Kodiak Sciences vs. Its Competitors Arcutis Biotherapeutics Immunocore ARS Pharmaceuticals Tarsus Pharmaceuticals Adaptive Biotechnologies Schrodinger Janux Therapeutics AbCellera Biologics Evotec Edgewise Therapeutics Kodiak Sciences (NASDAQ:KOD) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Do institutionals and insiders have more ownership in KOD or ARQT? 89.1% of Kodiak Sciences shares are held by institutional investors. 45.9% of Kodiak Sciences shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, KOD or ARQT? Kodiak Sciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Does the media refer more to KOD or ARQT? In the previous week, Arcutis Biotherapeutics had 7 more articles in the media than Kodiak Sciences. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 0 mentions for Kodiak Sciences. Arcutis Biotherapeutics' average media sentiment score of 0.99 beat Kodiak Sciences' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Kodiak Sciences Neutral Arcutis Biotherapeutics Positive Is KOD or ARQT more profitable? Kodiak Sciences has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -60.95%. Arcutis Biotherapeutics' return on equity of -80.66% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kodiak SciencesN/A -115.71% -54.17% Arcutis Biotherapeutics -60.95%-80.66%-32.94% Do analysts rate KOD or ARQT? Kodiak Sciences currently has a consensus target price of $9.00, suggesting a potential upside of 35.34%. Arcutis Biotherapeutics has a consensus target price of $19.40, suggesting a potential upside of 35.76%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has stronger valuation & earnings, KOD or ARQT? Arcutis Biotherapeutics has higher revenue and earnings than Kodiak Sciences. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKodiak SciencesN/AN/A-$176.21M-$3.63-1.83Arcutis Biotherapeutics$196.54M8.67-$140.04M-$1.04-13.74 SummaryArcutis Biotherapeutics beats Kodiak Sciences on 10 of the 15 factors compared between the two stocks. Get Kodiak Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KOD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOD vs. The Competition Export to ExcelMetricKodiak SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$346.92M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.8317.6228.7823.81Price / SalesN/A179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book2.338.508.275.54Net Income-$176.21M-$55.06M$3.25B$259.28M7 Day Performance-24.77%-3.99%-3.70%-4.64%1 Month Performance73.63%9.58%4.34%4.41%1 Year Performance148.13%6.70%25.90%17.95% Kodiak Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KODKodiak Sciences3.3316 of 5 stars$6.65+1.2%$9.00+35.3%+130.1%$346.92MN/A-1.8390Gap DownARQTArcutis Biotherapeutics2.7194 of 5 stars$14.96+0.7%$19.40+29.7%+50.7%$1.77B$196.54M-14.38150News CoverageUpcoming EarningsIMCRImmunocore1.7414 of 5 stars$33.94-3.5%$58.89+73.5%-16.7%$1.77B$310.20M-78.93320News CoverageUpcoming EarningsSPRYARS Pharmaceuticals3.204 of 5 stars$18.35+2.7%$31.00+68.9%+63.8%$1.76B$89.15M0.0090Upcoming EarningsTARSTarsus Pharmaceuticals2.5317 of 5 stars$41.75+0.6%$66.67+59.7%+74.2%$1.74B$182.95M-15.2950Positive NewsUpcoming EarningsADPTAdaptive Biotechnologies3.0058 of 5 stars$10.61-1.3%$10.57-0.4%+132.1%$1.63B$178.96M-11.05790Positive NewsUpcoming EarningsGap DownSDGRSchrodinger2.5882 of 5 stars$22.39+0.7%$32.75+46.3%-13.6%$1.63B$207.54M-8.51790Positive NewsUpcoming EarningsGap DownJANXJanux Therapeutics2.4078 of 5 stars$25.55-1.6%$91.89+259.6%-43.2%$1.54B$10.59M-18.7930Upcoming EarningsABCLAbCellera Biologics2.4221 of 5 stars$4.92-3.7%$8.75+77.8%+39.0%$1.52B$28.83M-8.79500News CoverageUpcoming EarningsGap UpEVOEvotec2.0865 of 5 stars$4.26flat$5.93+39.3%-13.2%$1.51B$862.40M0.004,827News CoverageEWTXEdgewise Therapeutics2.4487 of 5 stars$14.26+1.0%$40.00+180.5%-14.6%$1.49BN/A-9.2060News CoverageUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies ARQT Competitors IMCR Competitors SPRY Competitors TARS Competitors ADPT Competitors SDGR Competitors JANX Competitors ABCL Competitors EVO Competitors EWTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KOD Stock Alerts